Mesenchymal stem cells (MSCs) represent a promising tool for new clinical concepts in
supporting cellular therapy. Bone marrow (BM) was the first source reported to contain MSCs. …

Evidence has emerged that mesenchymal stem cells (MSCs) represent a promising population
for supporting new clinical concepts in cellular therapy. However, attempts to isolate …

Results from the main parts (24 weeks) of 2 concizumab phase 2 trials are presented:
explorer4 in hemophilia A (HA) or B (HB) with inhibitors (HAwI/HBwI) and explorer5 in HA. The …

Platelets are generally believed to be inactive in terms of de novo protein synthesis. On the
other hand, the presence of ribosomes and mRNA molecules is well established. Many …

BACKGROUND Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
differ in the severity of disease. We hypothesized that characteristics of SARS-…

Background Blood transfusion is the most common hospital procedure performed in the U
nited S tates. While inadequate physician transfusion medicine knowledge may lead to …

Despite current therapies, there remains an unmet need for treatment for patients with hemophilia.
The main parts of two phase 2 trials established clinical proof-of-concept for once-daily…

Factor VIII protein (FVIII) as a coagulation replacement factor has for decades been used as
the standard of care for management of people with haemophilia A. It is effective for …

Mesenchymal stem cells (MSCs) from bone marrow play a critical role in osteochondral
repair. A bone marrow clot forms within the cartilage defect either as a result of marrow …

Acquired hemophilia A (AHA) is due to autoantibodies against coagulation factor VIII (FVIII)
and most often presents with unexpected bleeding. In contrast to congenital hemophilia, the …